



## **Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit**

April 15, 2021

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.

The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido's website at <https://investors.kaleido.com/events-presentations>. An archived replay will be available for 90 days following the event.

### **About Kaleido Biosciences**

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit <https://kaleido.com/>.

### **Contacts:**

Kaleido Biosciences  
William Duke, Jr.  
Chief Financial Officer  
617-890-5772  
[william.duke@kaleido.com](mailto:william.duke@kaleido.com)

### **Investors**

Mike Biega  
Solebury Trout  
617-221-9660  
[mbiega@soleburytrout.com](mailto:mbiega@soleburytrout.com)

### **Media**

Amy Bonanno  
Solebury Trout  
914-450-0349  
[abonanno@soleburytrout.com](mailto:abonanno@soleburytrout.com)

SOURCE: Kaleido Biosciences